Accelerating mRNA Technology & Delivery Innovation Across Modalities

Spearheading End-to-End mRNA Therapeutic Development by Optimising Formulation & Delivery, De-Risking the Path to Clinic & Enhancing Manufacturing & Analytical Strategies to Realize the Full Potential of mRNA Medicines 

The mRNA therapeutics and LNP delivery landscapes are entering a new era of clinical ambition, technological innovation and strategic investment. From Moderna and Merck's Phase III progress in personalised mRNA cancer vaccines, to Eli Lilly's collaboration with METiS TechBio on tissue-targeted LNPs, momentum is building beyond conventional vaccine applications. Yet unlocking mRNA's therapeutic potential depends on optimising mRNA expression and durability, achieving targeted extrahepatic delivery and overcoming the analytical and manufacturing challenges of clinical development. 

For 2027, the 6th mRNA-Based Therapeutics & Non-Viral Delivery Summit Europe unites three established conferences into one integrated meeting. Bringing together the mRNA-Based Therapeutics, Lipid Nanoparticles Development and mRNA Process Development & CMC communities, the expanded summit connects RNA design, delivery innovation and manufacturing expertise to tackle challenges across the development pathway. 

Across two specialist content streams, R&D & Preclinical Development and Process Development & CMC, explore: 

Past attendees:

I really enjoyed the event. The engaging talks and the variety of speakers from across the globe truly stood out, offering diverse perspectives and insightful discussions on mRNA therapeutics. The location was very nice as well in Berlin. A great setting for networking and learning. Overall, it was a well-organized experience that felt both energizing and meaningful.

Senior Scientist, AstraZeneca

AstraZeneca logo, representing the global biopharmaceutical company advancing innovative medicines across oncology, rare diseases, cardiovascular, respiratory, immunology, and vaccine development.

Past attendees: 

The speaker lineup was excellent, with a strong balance between academic leaders and industry experts

Chief Business Officer & CMC Lead, CybernaX Bio

CybernaX Bio logo, representing a biotechnology company focused on advancing innovative mRNA therapeutics, nucleic acid technologies, and next-generation drug delivery solutions.

2027 speakers: 

Innovation thrives when diverse expertise comes together. By uniting the mRNA and non-viral delivery community, this meeting provides a unique platform to share knowledge, identify common challenges, and leverage synergies across different modalities. These interactions can spark new ideas, strengthen collaborations, and ultimately accelerate the translation of scientific innovation into meaningful patient impact

Associate Director GMP/CMC Drug Product, BioNTech

BioNTech logo, representing the biotechnology company pioneering mRNA-based medicines, immunotherapies, and next-generation treatments for cancer and infectious diseases.

RNA Engineering:

Optimising translation, expression durability and immune activation across mRNA, circRNA and xRNA. 

Targeted Non-Viral Delivery:

Advancing ionisable lipids, targeted LNPs, endosomal escape and extrahepatic delivery. 

Therapeutic Applications:

Exploring in vivo CAR-T, gene editing, oncology, respiratory and cardiometabolic therapies. 

RNA & LNP Manufacturing:

Improving RNA purity, circRNA recovery, LNP formulation and scalable production. 

Analytical & CMC Strategies:

Strengthening potency assays, product characterisation, stability and GMP readiness. 

AI & Automation:

Accelerating lipid discovery, RNA screening and automated DNA-to-mRNA workflows. 

Join 28+ expert speakers from AstraZeneca, BioNTech, Sanofi, Abogen, NeoVac and more in Berlin on 18–19 February 2027 to discover emerging data, benchmark development strategies and connect with potential partners advancing the next generation of RNA medicines. 

Explore the Full Event Guide

Discover what's bringing Europe's RNA therapeutics, non-viral delivery and CMC communities together in Berlin. 

  • 28+ Expert Speakers
    Hear from AstraZeneca, BioNTech, Sanofi, Abogen and emerging RNA innovators
  • 2 Specialist Content Streams
    Dive into R&D & Preclinical Development or Process Development & CMC, with shared plenaries bridging both
  • 3 Established Conferences United
    Connecting mRNA therapeutics, lipid nanoparticle development and mRNA manufacturing in one summit
  • 6+ Therapeutic Areas Explored
    From oncology and genetic diseases to respiratory, cardiometabolic, autoimmune and ocular applications
mRNA-Based Therapeutics & Non-Viral Delivery Europe

Europe’s RNA Development Community, Together

2

Main-Conference Tracks

30

Named Faculty Members 

3

Established Conference Communities Represented

Official Partners

Lead Partner

Expertise Partners

Exhibition Partners

Innovation Partner

Attending Companies Include

Conference speaker presenting insights on RNA therapeutics, mRNA development, and non-viral delivery innovation at a scientific industry summit.

Explore the Agenda

Discover the latest advances in RNA therapeutics, targeted non-viral delivery and mRNA manufacturing, from tissue-specific LNPs and emerging RNA modalities to GMP-ready processes.

Conference attendees and industry partners networking and discussing innovations in mRNA therapeutics and drug delivery technologies.

Partner With Us

Showcase your RNA technologies, delivery platforms and manufacturing solutions to biopharma decision-makers seeking partners to overcome critical development challenges.

Audience members attending a scientific conference session focused on mRNA therapeutics, drug delivery, and nucleic acid medicine development.

Join Biopharma Experts

Connect with Europe's therapeutic R&D, non-viral delivery and CMC experts in one integrated summit, bringing together the teams advancing next-generation mRNA medicines towards the clinic.